Advertisement
Global  

“News neutrality by unbiased coverage”
One News Page
> >

CRISPR Therapeutics Announces Proposed Public Offering of Common Shares

GlobeNewswire Wednesday, 19 September 2018
ZUG, Switzerland and CAMBRIDGE, Mass., Sept. 19, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced that it is commencing an underwritten public offering of $200,000,000 of its common shares. In addition, the underwriters will have a 30-day option to purchase up to $30,000,000 of additional common shares at the public offering price less the underwriting discount.Goldman Sachs & Co. LLC, Piper Jaffray & Co., Barclays Capital Inc. and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering. Guggenheim Securities, LLC and Needham & Company, LLC are acting as co-managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

An automatic shelf registration statement on Form S-3ASR relating to these securities has been filed with the Securities and Exchange Commission (SEC) and has become effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering will be made only by means of a prospectus. A copy of the prospectus supplement relating to the offering will be filed with the SEC and may be obtained, when available, from Goldman, Sachs & Co. LLC by mail at 200 West Street, New York, NY 10282, Attention: Prospectus Department, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; from Piper Jaffray & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email at prospectus@pjc.com; Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (888) 603-5847 or by email at Barclaysprospectus@broadridge.com; or from Wells Fargo Securities, LLC, Attn: Equity Syndicate Department, 375 Park Avenue, New York, New York 10152, or by email at cmclientsupport@wellsfargo.com, or by telephone at (800) 326-5897. 

*About CRISPR Therapeutics*

CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts.

*Cautionary Note Regarding Forward-Looking Statements*

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding CRISPR Therapeutics’ anticipated public offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, such as the intended offering terms, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in CRISPR Therapeutics’ Annual Report on Form 10-K for the year ended December 31, 2017, as filed with the SEC on March 8, 2018, the prospectus supplement related to the public offering and other filings that CRISPR Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent CRISPR Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. CRISPR Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

CRISPR Investor Contact:
Susan Kim
617-307-7503
susan.kim@crisprtx.com

CRISPR Media Contact:
Jennifer Paganelli
WCG on behalf of CRISPR
347-658-8290
jpaganelli@wcgworld.com
0
shares
ShareTweetSavePostSend
 

Recent related news from verified sources

Scorpio Tankers Inc. Announces Public Offering of Common Shares

MONACO, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Scorpio Tankers Inc. (NYSE: STNG) (“Scorpio Tankers,” or the “Company”) announced today that it intends to...
GlobeNewswire - Press ReleasesAlso reported by •Business Wire

Scorpio Bulkers Inc. Announces an Investment of $100.0 Million in a Scorpio Tankers Inc. Capital Raise

MONACO, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Scorpio Bulkers Inc. (NYSE:SALT) (“Scorpio Bulkers,” or the “Company”) announced today that the Company has...
GlobeNewswire - Press ReleasesAlso reported by •Business Wire

Longevity Acquisition Corporation Announces Separate Trading of its Ordinary Shares, Rights and Warrants, Commencing October 15, 2018

New York, NY, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Longevity Acquisition Corporation (the “Company”) (NASDAQ: LOACU) announced today that, commencing on October...
GlobeNewswire - Press Releases

ELBIT IMAGING ANNOUNCES THAT GAMIDA CELL HAS MADE A PUBLIC FILING WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION IN CONNECTION WITH A PROPOSED IPO IN THE UNITED STATES

Tel Aviv, Israel, Oct. 17, 2018 (GLOBE NEWSWIRE) -- *Elbit Imaging Ltd. (TASE, NASDAQ: EMITF)* (“*Elbit*”) announced today, further to its press release...
GlobeNewswire - Press Releases

You Might Like


Tweets about this


Other recent news in Press Releases

BTU Clarifies Previous Release Regarding Acquiring Two Strategic Properties Contiguous to Great Bear's Dixie Project, Red Lake District, CANADACAGW Submits Comments to FCC on Use of Unlicensed SPECTRUM for Autonomous Vehicles
MTV Studios and Facebook Watch Join Forces to Reimagine MTV’s The REAL WORLD Around the World with Three All New SeasonsThe BURGER KING® Brand Creates a HALLOWEEN Sandwich Clinically Proven to Induce Nightmares

Recent related videos from verified sources

Uber IPO Proposals Puts Company Value At $120 Billion [Video]Uber IPO Proposals Puts Company Value At $120 Billion 00:32

Reuters reports Uber Technologies Inc could be valued at $120 billion when it finally goes public. What is that figure based on? The Wall Street Journal reports its based on proposals made by banks..

Credit: Wochit Business - Published

Share Of NIO Surge After Deliveries Beat Expectations [Video]Share Of NIO Surge After Deliveries Beat Expectations 00:37

According to Business Insider, shares for the Tesla of China surged after their deliveries beat expectations. Shares of Nio, surged as much as 8$ early Monday after the company said its quarterly..

Credit: Wochit Business - Published

Upwork Prices Its IPO At $15 [Video]Upwork Prices Its IPO At $15 00:36

According to Markets Insider, Upwork, the largest freelancers network, is has gone public today. It is priced at $15 a share, raising $187 million through its initial public offering. The company says..

Credit: Wochit Business - Published

Blue Apron Falls To Record Low [Video]Blue Apron Falls To Record Low 00:33

Business Insider reports Blue Apron hit a record low of $1.50 a share on Tuesday. The meal-kit maker announced it was launching a pilot program for on-demand delivery. The pilot program would only be..

Credit: Wochit Business - Published

Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2018 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Contact us  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest